Vaccinex Net Worth
Vaccinex Net Worth Breakdown | VCNX |
Vaccinex Net Worth Analysis
Vaccinex's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vaccinex's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vaccinex's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vaccinex's net worth analysis. One common approach is to calculate Vaccinex's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vaccinex's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vaccinex's net worth. This approach calculates the present value of Vaccinex's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vaccinex's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vaccinex's net worth. This involves comparing Vaccinex's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vaccinex's net worth relative to its peers.
Enterprise Value |
|
To determine if Vaccinex is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vaccinex's net worth research are outlined below:
| Vaccinex generated a negative expected return over the last 90 days | |
| Vaccinex has high historical volatility and very poor performance | |
| Vaccinex has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 570 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (13.7 M). | |
| Vaccinex currently holds about 11.4 M in cash with (17.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. | |
| Vaccinex has a poor financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Vaccinex reports Q3 figures |
Vaccinex uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vaccinex. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vaccinex's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Vaccinex's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaccinex is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaccinex backward and forwards among themselves. Vaccinex's institutional investor refers to the entity that pools money to purchase Vaccinex's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 0.0 | Tacita Capital Inc. | 2024-06-30 | 0.0 | Point72 Asset Management, L.p. | 2024-09-30 | 166 K | Armistice Capital, Llc | 2024-09-30 | 164 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.2 K | Tower Research Capital Llc | 2024-06-30 | 1.3 K | Group One Trading, Lp | 2024-06-30 | 67.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 53.0 | Royal Bank Of Canada | 2024-06-30 | 39.0 | Bank Of America Corp | 2024-06-30 | 8.0 | Capital Advisors, Ltd. Llc | 2024-09-30 | 3.0 |
Follow Vaccinex's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.69 M.Market Cap |
|
Project Vaccinex's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.58) | (5.86) | |
| Return On Capital Employed | 10.02 | 10.52 | |
| Return On Assets | (5.58) | (5.86) | |
| Return On Equity | 8.76 | 9.20 |
When accessing Vaccinex's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vaccinex's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vaccinex's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Vaccinex's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaccinex. Check Vaccinex's Beneish M Score to see the likelihood of Vaccinex's management manipulating its earnings.
Evaluate Vaccinex's management efficiency
Vaccinex has return on total asset (ROA) of (4.9564) % which means that it has lost $4.9564 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.5909) %, meaning that it created substantial loss on money invested by shareholders. Vaccinex's management efficiency ratios could be used to measure how well Vaccinex manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Vaccinex's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 9.20 in 2024, whereas Return On Tangible Assets are likely to drop (5.86) in 2024. At this time, Vaccinex's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 8.9 M in 2024, whereas Non Currrent Assets Other are likely to drop (1.05) in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (4.98) | (4.74) | |
| Tangible Book Value Per Share | (4.98) | (4.74) | |
| Enterprise Value Over EBITDA | (0.15) | (0.16) | |
| Price Book Value Ratio | (1.87) | (1.96) | |
| Enterprise Value Multiple | (0.15) | (0.16) | |
| Price Fair Value | (1.87) | (1.96) | |
| Enterprise Value | 3 M | 2.9 M |
Leadership effectiveness at Vaccinex is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 21.5578 | Revenue 356 K | Quarterly Revenue Growth (0.81) | Revenue Per Share 0.318 | Return On Equity (7.59) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaccinex insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaccinex's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vaccinex insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vaccinex Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 25th of October 2024 Other Reports | ViewVerify | |
| 16th of October 2024 Other Reports | ViewVerify |
Vaccinex Earnings per Share Projection vs Actual
Vaccinex Corporate Management
| Jill CPA | Chief Officer | Profile | |
| Jill Sanchez | Interim Controller | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ernest Smith | Senior Officer | Profile | |
| Maurice Zauderer | CEO, CoFounder | Profile | |
| Elizabeth Evans | COO Medicine | Profile | |
| John Leonard | Senior Development | Profile |
Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.